Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK8 | P49336 | 6/20 | 0.68 |
| ▸ | CDK7 | P50613 | 2/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.52 |
| ▸ | CDK1 | P06493 | 2/20 | 0.52 |
| ▸ | FES | P07332 | 2/20 | 0.52 |
| ▸ | ROS1 | P08922 | 2/20 | 0.52 |
| ▸ | FER | P16591 | 2/20 | 0.52 |
| ▸ | FLT4 | P35916 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 2/20 | 0.52 |
| ▸ | IRAK1 | P51617 | 2/20 | 0.52 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.52 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.52 |
| ▸ | MARK2 | Q7KZI7 | 2/20 | 0.52 |
| ▸ | MINK1 | Q8N4C8 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | SLK | Q9H2G2 | 2/20 | 0.52 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.52 |
| ▸ | STK17A | Q9UEE5 | 2/20 | 0.52 |
| ▸ | MAP4K5 | Q9Y4K4 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13808678 | 0.84 | RIPK1 (0.55) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL12410716 | 0.83 | CDK8 (0.67) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL27677303 | 0.83 | NAMPT (0.57) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL18129803 | 0.83 | CDK8 (0.52) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL27732330 | 0.83 | RIPK1 (0.56) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL29004632 | 0.82 | CDK8 (1.00) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL298264 | 0.81 | RIPK1 (0.55) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL415994 | 0.81 | CDK8 (0.68) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL4117054 | 0.80 | RIPK1 (0.70) | CDK8CDK7MAP4K4CHEK2CDK1 | |
| SCHEMBL29378344 | 0.80 | RIPK1 (0.70) | CDK8CDK7MAP4K4CHEK2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240116920-A1 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | KOREA PHARMA CO., LTD. (KR) | 2024-04-11 | — | — | US | disclosed |
| US-20220220109-A1 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | KOREA PHARMA CO., LTD. (KR) | 2022-07-14 | — | — | US | disclosed |
| CN-111518096-B | Janus kinase JAK family inhibitor and preparation and application thereof | 江苏威凯尔医药科技有限公司 | 2022-02-11 | — | — | CN | disclosed |
| WO-2020242204-A1 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | 주식회사한국파마 | 2020-12-03 | — | — | WO | disclosed |
| EP-2496086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. | 2012-05-17 | — | — | US | disclosed |
| EP-2427433-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | Plexxikon, Inc. (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010129570-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | PLEXXIKON, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122860-A1 | SOLID FORMS OF SULFONAMIDES AND AMINO ACIDS | BRAF, RAF1, ARAF | CDK8 271/4885CDK7 300/4885MAP4K4 11/4885 |
| US-20220220109-A1 | JAK INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | JAK1, JAK2, JAK3 | CDK8 532/4885CDK7 422/4885MAP4K4 163/4885 |
| US-20240116920-A1 | NOVEL JAK-SPECIFIC INHIBITOR COMPOUND AND METHOD FOR PREPARING SAME | JAK1, JAK2, JAK3 | CDK8 243/4885CDK7 328/4885MAP4K4 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.